transfusionrel
acut
lung
injuri
trali
lifethreaten
complic
acut
respiratori
distress
occur
within
hour
blood
transfus
trali
one
lead
caus
transfusionrel
fatal
specif
therapi
unavail
neutrophil
recogn
major
pathogen
cell
wherea
regulatori
cell
dendrit
cell
appear
import
protect
trali
pathogenesi
howev
complex
incomplet
understood
frequent
postul
complement
system
play
import
role
trali
pathogenesi
articl
assess
evid
regard
involv
complement
trali
human
anim
studi
hypothes
potenti
connect
complement
system
neutrophil
trali
addit
draw
parallel
trali
acut
pulmonari
disord
acut
lung
injuri
acut
respiratori
distress
syndrom
regard
involv
complement
conclud
even
though
role
complement
trali
pathogenesi
seem
plausibl
studi
investig
role
complement
trali
remark
limit
number
also
present
conflict
find
differ
type
trali
anim
model
divers
experiment
condit
composit
gastrointestin
microbiota
may
perhap
factor
contribut
discrep
systemat
studi
warrant
shed
light
contribut
complement
cascad
trali
underli
clinic
condit
patient
influenc
suscept
trali
well
transfus
factor
antibodymedi
vs
nonantibodymedi
import
take
consider
research
contribut
complement
significantli
increas
understand
role
complement
trali
may
potenti
result
promis
new
treatment
strategi
transfusionrel
acut
lung
injuri
trali
syndrom
acut
respiratori
distress
occur
within
hour
blood
transfus
trali
character
acut
onset
noncardiogen
pulmonari
edema
one
lead
caus
transfusionrel
fatal
specif
therapi
lack
trali
particularli
preval
critic
ill
patient
incid
report
report
surviv
rate
low
compar
acut
lung
injuri
control
patient
pathogenesi
trali
complic
incomplet
understood
gener
model
consid
repres
trali
pathophysiolog
first
hit
relat
underli
clinic
condit
patient
eg
inflamm
wherea
second
hit
convey
factor
transfus
blood
product
second
hit
factor
may
antibodi
around
trali
case
antihuman
leukocyt
antigen
hla
class
ii
antihuman
neutrophil
antigen
hna
antibodi
antibodyindepend
factor
biolog
respons
modifi
eg
lipid
trali
mainli
occur
hit
combin
although
case
describ
report
onset
trali
healthi
subject
eg
anim
model
trali
significantli
contribut
current
understand
pathophysiolog
base
autopsi
report
trali
patient
trali
anim
model
vitro
trali
experi
neutrophil
pmn
consid
key
pathogen
cell
antibodi
nonantibodymedi
trali
transfus
recipi
pmn
suggest
exert
pathogen
effect
trali
direct
activ
product
reactiv
oxygen
speci
ro
format
neutrophil
extracellular
trap
net
suggest
use
murin
trali
model
antimajor
histocompat
complex
mhc
class
antibodi
may
bind
pulmonari
endothelium
subsequ
sequest
pmn
via
result
pmn
activ
trali
induct
addit
use
murin
model
antimhc
class
antibodymedi
trali
pmn
ro
found
critic
requir
trali
induct
demonstr
vivo
pmn
deplet
use
knockout
mice
furthermor
platelet
shown
induc
net
format
trali
mice
suggest
net
may
therebi
induc
lung
injuri
via
direct
toxic
pulmonari
endotheli
cell
addit
net
shown
form
upon
direct
prime
pmn
antibodi
regard
trali
pmn
also
demonstr
interact
von
willebrand
factor
via
carrier
antigen
enabl
antibodyinduc
signal
via
result
pmn
activ
agglutin
next
monocytesmacrophag
may
exert
pathogen
effect
trali
addit
red
blood
cell
rbc
transfus
product
transfus
recipi
suggest
elicit
pathogen
effect
trali
rat
mous
model
interestingli
target
recipi
red
blood
cell
red
blood
specif
antibodi
shown
prevent
occurr
trali
murin
model
hand
regulatori
cell
dendrit
cell
shown
major
cell
protect
trali
demonstr
use
murin
model
trali
much
research
requir
understand
specif
natur
pathogen
immun
respons
occur
trali
complex
dissect
pathophysiolog
trali
illustr
controversi
arisen
involv
recipi
platelet
one
controversi
appear
involv
complement
system
trali
focu
current
articl
complement
system
form
import
part
innat
immun
system
erad
microbi
pathogen
apoptot
cell
immun
complex
leav
healthi
cell
intact
activ
complement
system
need
effect
control
prevent
damag
host
sever
complement
regulatori
protein
present
blood
transfus
foreign
blood
cell
enter
bodi
presenc
alloantibodi
antigen
polymorph
recipi
tissu
complement
system
activ
result
advers
transfus
reaction
complement
system
compos
around
protein
either
resid
blood
membranebound
complement
system
activ
via
three
differ
rout
name
classic
pathway
cp
lectin
pathway
lp
altern
pathway
ap
sever
diseas
link
unwant
overactiv
complement
system
cp
activ
via
alloand
autoantibodi
bound
rbc
form
follow
rbc
transfus
present
autoimmun
hemolyt
anemia
addit
mutat
result
alter
function
lack
complement
regulatori
protein
often
associ
overactiv
ap
seen
atyp
hemolyt
urem
syndrom
paroxysm
nocturn
hemoglobinuria
contrast
cp
ap
howev
diseas
relat
lp
rel
poorli
defin
studi
indic
inhibit
lp
might
therapeut
relev
ischemia
reperfus
injuri
although
mechan
remain
poorli
understood
furthermor
larg
part
popul
defici
mannos
bind
lectin
mbl
key
player
initi
lp
mbl
pathway
activ
effect
occur
rel
mild
predomin
result
sever
infect
neonat
antibodi
main
driver
cp
interestingli
complement
shown
effect
activ
igg
hexam
assembl
cell
surfac
addit
cp
also
activ
via
bind
creactiv
protein
crp
phosphocholin
site
expos
disrupt
plasma
membran
bind
igg
igm
crp
result
activ
turn
cleav
cleavag
product
form
convertas
cp
convertas
cleav
coval
bind
surfac
wherea
chemoattract
immun
cell
bind
surfac
eventu
lead
format
convertas
cleav
gener
potent
chemoattract
form
basi
membran
attack
complex
mac
compos
activ
lp
occur
carbohydr
moieti
microbi
pathogen
bound
mbl
ficolin
bind
result
activ
mblassoci
serin
proteas
masp
turn
cleav
form
convertas
analog
activ
via
cp
ap
import
player
immun
system
believ
complement
activ
heavili
reli
amplif
loop
provid
ap
although
ap
initi
spontan
low
rate
due
turnov
h
plasma
main
function
lie
amplifi
deposit
cellular
surfac
factor
b
fb
bind
molecul
cleav
factor
fd
result
format
ap
convertas
convertas
also
cleav
incorpor
anoth
molecul
result
format
ap
convertas
similar
cplp
convertas
result
cleavag
gener
mac
sever
fluidphas
membranebound
complement
regul
inhibit
activ
complement
system
exampl
fluid
phase
regul
inhibitor
bind
protein
inhibit
activ
via
cp
lp
hand
fluidphas
regul
factor
h
fh
fhlike
inhibit
ap
addit
recent
discov
fhrelat
protein
fhr
believ
fine
tune
regulatori
capac
fh
howev
vivo
evid
lack
vitro
evid
often
contradict
cell
express
sever
membranebound
regul
like
complement
receptor
cr
also
known
membran
cofactor
protein
mcp
also
known
decayacceler
factor
daf
final
fluid
phase
regul
vitronectin
clusterin
abl
prevent
format
mac
wherea
factor
fi
glycoprotein
downregul
complement
system
cleavag
deposit
inact
form
presenc
cofactor
fh
mcp
complement
system
schemat
summar
figur
trali
frequent
trigger
antibodi
present
transfus
product
crp
also
play
import
pathogen
role
trali
increas
trali
patient
involv
complement
specif
cp
trali
appear
plausibl
although
suggest
complement
system
play
role
trali
number
studi
directli
investig
appear
surprisingli
limit
regard
human
studi
ambruso
et
al
report
publish
abstract
activ
complement
antihla
class
iimedi
trali
patient
sampl
absent
pretransfus
sampl
interestingli
author
found
complement
activ
product
transfus
onset
trali
symptom
suggest
activ
complement
compon
transfus
product
play
role
trali
reaction
prospect
random
doubleblind
crossov
studi
palfi
et
al
look
concentr
preand
posttransfus
plasma
sampl
intens
care
patient
receiv
plasma
multipar
donor
compar
receiv
plasma
nontransfus
nullipar
women
result
breakdown
deposit
fig
conclud
plasma
multipar
blood
donor
may
impair
pulmonari
function
intens
care
unit
patient
author
find
differ
level
notabl
howev
posttransfus
reaction
occur
case
transfus
plasma
multipar
donor
patient
typic
trali
reaction
mild
case
trali
luca
et
al
found
complement
fix
igm
antibodi
serum
femal
donor
donor
pool
platelet
concentr
may
trigger
trali
due
interdonor
incompat
dri
et
al
perform
autopsi
trali
patient
observ
presenc
macrophag
alveolar
air
space
describ
occur
hour
infus
activ
complement
rabbit
lung
lack
intraalveolar
macrophag
howev
may
yet
occur
trali
patient
die
hour
initi
clinic
sign
pulmonari
edema
studi
use
anim
model
trali
also
assess
contribut
compon
complement
system
colleagu
use
murin
model
trali
base
lipopolysaccharid
lp
prime
infus
antimhc
class
antibodi
result
increas
level
bronchoalveolar
lavag
fluid
balf
attenu
pulmonari
level
associ
improv
lung
injuri
score
howev
effect
level
balf
addit
despit
administr
high
level
pulmonari
system
inflammatori
cytokin
persist
includ
macrophag
inflammatori
protein
mip
murin
homolog
furthermor
strait
colleagu
found
import
role
murin
trali
use
antimhc
class
antibodi
balbc
mice
mice
defici
receptor
protect
trali
requir
trali
induct
suggest
relat
fact
adult
male
mice
suscept
trali
wherea
adult
femal
mice
appar
resist
femal
mice
approxim
much
plasma
male
subtyp
male
mice
present
femal
may
least
part
explain
sexspecif
differ
trali
suscept
support
data
demonstr
infus
femal
mice
plasma
male
wt
male
mice
enabl
trali
wherea
infus
plasma
male
fail
induc
trali
looney
cowork
hand
describ
occurr
trali
balbc
mice
hour
trali
fig
complement
system
complement
system
initi
bind
recognit
molecul
lectin
classic
pathway
lp
cp
lp
mbl
ficolin
fic
complex
masp
protein
recogn
glycan
moieti
pathogen
surfac
complex
compos
molecul
recogn
antibodyantigen
complex
activ
masp
protein
cleav
deposit
surfac
via
thioester
subsequ
cleavag
allow
format
convertas
cleav
via
ap
convertas
also
form
fluid
phase
compos
h
bb
larg
product
upon
fb
cleavag
fd
deposit
surfac
ap
convertas
stabil
properdin
p
altern
pathway
function
amplif
loop
increas
deposit
number
deposit
molecul
increas
becom
prefer
substrat
convertas
initi
termin
pathway
togeth
sever
molecul
form
lytic
pore
known
membraneattack
complex
mac
b
breakdown
deposit
attach
surfac
regul
via
multipl
mechan
fh
daf
complement
receptor
abl
compet
fb
prevent
format
acceler
decay
ap
convertas
addit
fh
mcp
function
cofactor
serin
proteas
fi
cleav
inact
form
releas
fragment
also
aid
fi
cleav
plasma
proteas
cleav
last
fragment
leav
last
antigen
fragment
attach
surfac
induct
inject
suggest
dispens
murin
trali
differ
studi
strait
et
al
looney
et
al
may
explain
time
experiment
endpoint
inject
minut
studi
strait
et
al
wherea
hour
studi
looney
et
al
addit
observ
differ
may
due
natur
anim
hous
may
affect
composit
gastrointestin
microbiota
therebi
suscept
trali
furthermor
studi
sach
et
al
use
ex
vivo
rat
model
trali
complement
found
requir
trali
induct
trali
induct
depend
densiti
cognat
antigen
trali
occur
complementfre
environ
earlier
ex
vivo
trali
studi
seeger
colleagu
use
rabbit
lung
rabbit
plasma
suggest
serv
sourc
complement
induc
trali
togeth
antibodi
pmn
studi
howev
direct
investig
regard
contribut
complement
studi
mention
provid
evid
support
involv
complement
trali
summar
tabl
pmn
key
pathogen
cell
trali
exert
effect
direct
activ
ro
product
releas
net
interestingli
innat
immun
system
abl
activ
pmn
via
differ
effector
molecul
igg
bound
target
recogn
pmn
via
receptor
degrad
product
recogn
sever
cr
gener
complement
activ
potent
chemoattract
recognit
substrat
result
pmn
activ
ro
product
net
format
immun
complex
capabl
bind
activ
inhibitori
express
innat
immun
effector
cell
includ
pmn
ro
respons
mediat
igg
influenc
combin
isoform
express
pmn
pmn
activ
igg
elicit
robust
ro
respons
shown
block
suffici
inhibit
immun
complexmedi
ro
product
set
autoimmun
arthriti
next
activ
via
immun
complex
ro
product
pmn
also
occur
activ
furthermor
import
block
complementmedi
pmn
activ
ro
product
also
shown
vivo
antineutrophil
cytoplasm
autoantibodi
model
glomerulonephr
suggest
receptor
mediat
pmn
activ
ro
format
antineutrophil
cytoplasm
autoantibodyinduc
glomerulonephr
importantli
shown
product
ro
high
import
induc
net
sever
autoimmun
diseas
character
presenc
immun
complex
vivo
vitro
studi
shown
immun
complex
induc
releas
net
via
bind
addit
immun
complex
activ
complement
system
via
cp
import
net
format
first
shown
mice
found
pmn
mice
form
net
also
guglietta
et
al
report
net
format
set
small
intestin
tumorigenesi
studi
circul
lp
found
upregul
pmn
result
net
format
induct
coagul
stimul
protumorigen
neutrophilia
addit
shown
pathogen
opson
igg
induc
net
format
bacteria
opson
igg
alon
furthermor
involv
releas
net
net
induct
antibodi
immun
complex
greatli
enhanc
pmn
first
prime
rabbit
rabbit
plasma
may
serv
sourc
complement
induc
sever
lung
edema
increas
lung
vascular
permeabl
ex
vivo
rabbit
lung
model
togeth
antibodi
pmn
addit
studi
shown
link
activ
instanc
use
kbxn
mous
serum
transferinduc
arthriti
mous
model
express
human
pmn
lack
activ
mice
shown
cross
talk
promot
inflammatori
arthriti
mice
taken
togeth
complement
system
potent
system
activ
pmn
induc
ro
product
net
format
process
also
describ
occur
trali
assess
potenti
contribut
complement
trali
parallel
may
drawn
form
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
activ
complement
system
play
import
role
ali
caus
highli
pathogen
virus
influenza
viru
sever
acut
respiratori
syndrom
shown
infect
human
host
highli
pathogen
virus
influenza
result
complement
activ
format
addit
balf
serum
mice
human
infect
fatal
viru
contain
increas
level
furthermor
shown
ali
induc
play
relev
role
excess
complement
activ
includ
gener
sever
murin
vivo
studi
use
ali
induc
shown
benefici
effect
block
ali
addit
also
directli
impact
vascular
permeabl
activ
endotheli
cell
also
activ
trali
russkamp
et
al
observ
alveolar
inflamm
increas
recruit
leukocyt
alveolar
air
space
sever
alveolarcapillari
barrier
dysfunct
upon
intratrach
administr
mice
author
demonstr
role
ccchemokin
receptor
model
ali
furthermor
discuss
play
import
role
ro
gener
format
net
similar
trali
ro
net
also
shown
play
role
ali
notabl
suggest
intravascular
activ
pmn
may
relat
gener
ro
result
onset
ali
studi
underlin
import
mediat
ali
may
support
investig
role
trali
ard
seriou
frequent
complic
multipl
medic
surgic
intervent
pneumonia
sepsi
aspir
gastric
content
common
risk
factor
like
trali
pmn
appear
play
strong
role
pathogenesi
ard
ard
occur
within
week
known
clinic
insult
present
newworsen
respiratori
symptom
case
unknown
clinic
event
role
complement
system
ard
extens
studi
detect
polytrauma
patient
risk
develop
ard
monitor
plasma
suggest
identifi
polytrauma
patient
high
risk
ard
earli
stage
diseas
contrast
differ
studi
patient
risk
ard
develop
due
major
nonthorac
trauma
fungemia
gramneg
bacteremia
hypotens
last
hour
found
use
predictor
ard
yet
anoth
studi
schein
colleagu
investig
patient
septic
shock
found
indic
effect
complement
activ
whatsoev
develop
ard
discrep
studi
may
relat
differ
ard
etiolog
appear
complement
system
may
perhap
play
role
ard
heterogen
etiolog
ard
add
complex
care
consid
studi
exact
role
differ
complement
protein
variou
type
ard
may
also
true
assess
role
complement
trali
underli
clinic
condit
patient
also
influenc
suscept
trali
addit
transfus
factor
antibodymedi
vs
nonantibodymedi
taken
account
frequent
assum
complement
system
part
trali
pathogenesi
hypothet
seem
plausibl
outlin
articl
studi
systemat
investig
role
complement
trali
howev
appear
surprisingli
limit
number
moreov
report
studi
demonstr
conflict
data
regard
complement
involv
trali
appar
controversi
may
least
part
explain
differ
type
trali
anim
model
vari
experiment
condit
may
possibl
includ
manufactur
process
use
gener
antibodi
may
differ
studi
may
consequ
differenti
impact
antibodyfc
glycosyl
composit
therebi
interact
fc
receptor
complement
addit
controversi
may
possibl
due
composit
gastrointestin
microbiota
influenc
chang
environment
anim
hous
condit
specif
pathogenfre
vs
barrierfre
hous
barrierfre
mice
shown
hypersuscept
trali
wherea
specif
pathogenfre
mice
resist
trali
unless
prime
lp
fecal
transfer
barrierfre
mice
specif
pathogenfre
mice
could
restor
suscept
trali
indic
role
gastrointestin
microbiota
trali
overal
reveal
need
systemat
indepth
investig
potenti
contribut
variou
complement
cascad
compon
induc
trali
perform
use
trali
anim
model
includ
use
complement
compon
knockout
mice
test
avail
specif
complement
cascad
inhibitor
well
trali
patient
sampl
underli
clinic
condit
patient
influenc
suscept
trali
well
transfus
factor
antibodi
vs
biolog
respons
modifi
taken
account
latter
investig
shed
light
relev
complement
system
trali
may
open
new
therapeut
avenu
explor
combat
trali
exampl
eculizumab
block
antibodi
antibodi
target
fh
